126352-69-0 Usage
Description
4,5,6,7-Tetrahydropyrazolo[1,5-a]pyrimidine is a chemical compound belonging to the class of pyrazolopyrimidines. It is characterized by its unique molecular structure, which consists of a fused pyrazole and pyrimidine ring system. 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE has garnered significant interest due to its potential applications in various fields, particularly in the pharmaceutical industry.
Uses
Used in Pharmaceutical Industry:
4,5,6,7-Tetrahydropyrazolo[1,5-a]pyrimidine is used as a fibroblast growth factor receptor (FGFR) inhibitor for the treatment of FGFR3-associated diseases. FGFR3 is a receptor tyrosine kinase that plays a crucial role in cell proliferation, differentiation, and migration. Abnormalities in FGFR3 have been linked to various diseases, including certain types of cancer.
In Cancer Treatment:
4,5,6,7-Tetrahydropyrazolo[1,5-a]pyrimidine is employed as an FGFR inhibitor to target and inhibit the activity of FGFR3, thereby disrupting the signaling pathways that promote cancer cell growth and proliferation. 4,5,6,7-TETRAHYDROPYRAZOLO[1,5-A]PYRIMIDINE has shown potential in treating FGFR3-associated cancers, such as bladder, lung, and breast cancers, among others. By inhibiting FGFR3, this compound can help slow down or stop the progression of these cancers, offering a promising therapeutic option for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 126352-69-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,6,3,5 and 2 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 126352-69:
(8*1)+(7*2)+(6*6)+(5*3)+(4*5)+(3*2)+(2*6)+(1*9)=120
120 % 10 = 0
So 126352-69-0 is a valid CAS Registry Number.
InChI:InChI=1/C6H9N3/c1-3-7-6-2-4-8-9(6)5-1/h2,4,7H,1,3,5H2
126352-69-0Relevant articles and documents
CHEMICAL COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
-
Paragraph 001018; 001019; 001020, (2018/08/12)
The present disclosure relates to novel sulfonylurea and sulfonyl thiourea compounds and related compounds and their use in treating a disease or condition responsive to modulation of cytokines such as IL-1β and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
Cephem compounds
-
, (2008/06/13)
The invention relates to an antimicrobial compound of the formula: STR1 wherein R1 is amino or a protected amino group, R2 is lower alkyl, lower alkenyl, carboxy (lower) alkyl or protected carboxy(lower)alkyl, R3 is hydrogen, lower alkyl, hydroxy(lower)alkyl, protected hydroxy(lower)alkyl, amino(lower)alkyl, protected amino(lower)alkyl or lower alkanoyl, R4 is hydrogen, lower alkyl or lower alkylthio, and Z is N or CH or a pharmaceutically acceptable salt thereof.